Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Asset Writedowns and Impairment (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of Asset Writedowns and Impairment readings, the most recent being $2.7 million for Q4 2025.

  • On a quarterly basis, Asset Writedowns and Impairment rose 2.09% to $2.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $9.5 million, a 5.01% decrease, with the full-year FY2025 number at $9.5 million, down 5.02% from a year prior.
  • Asset Writedowns and Impairment hit $2.7 million in Q4 2025 for Tandem Diabetes Care, down from $3.2 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $3.6 million in Q3 2024 to a low of $143000.0 in Q1 2021.
  • Median Asset Writedowns and Impairment over the past 5 years was $1.5 million (2023), compared with a mean of $1.7 million.
  • Biggest five-year swings in Asset Writedowns and Impairment: crashed 83.41% in 2021 and later skyrocketed 491.61% in 2022.
  • Tandem Diabetes Care's Asset Writedowns and Impairment stood at $2.1 million in 2021, then fell by 11.05% to $1.8 million in 2022, then fell by 19.32% to $1.5 million in 2023, then soared by 81.61% to $2.7 million in 2024, then increased by 2.09% to $2.7 million in 2025.
  • The last three reported values for Asset Writedowns and Impairment were $2.7 million (Q4 2025), $3.2 million (Q3 2025), and $2.1 million (Q2 2025) per Business Quant data.